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CASPASE-DEPENDENT APOPTOSIS
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Hemangiomas are the most common congenital vascular and benign tumor in infants and children. Most hemangiomas do not 
cause major symptoms to require intervention, however, the larger hemangiomas have tendency to bleed and may require surgical 
removal. Experimental studies have demonstrated the role of urokinase plasminogen activator (u-PA), especially cell surface u-PA, 
as an initiator of extra-cellular matrix proteolysis and associated tumor cell invasion. Aim: To examine, whether the antitumor 
effects of a specific nutrient mixture are due to induction of apoptosis by inhibition of u-PA. Materials and Methods: A nutrient 
mixture containing lysine, proline, ascorbic acid, and green tea extract which has showed anticancer activity against a number 
of cancer cell lines was used as an experimental composition. EOMA cells were grown in appropriate media with antibiotics in 24-
well tissue culture plates. At near confluence, the cells were treated with nutrition mixture at 10, 100, 1000 µg/ml in triplicate. 
Analysis of u-PA activity was carried out by fibrin zymography. Morphological changes and caspase activation associated with 
apoptosis induction was checked by H&E staining and Live Green caspase assay, respectively. Apoptosis inducing anticancer drug 
camptothecin (10 µM) was used as positive control. Results: The nutrition mixture exhibited dose response toxicity with maximum 
toxicity 55% (p < 0.001) at 1000 µg/ml. EOMA cells expressed u-PA, which was inhibited by nutrition mixture in a dose-dependent 
manner. The caspase analysis revealed a dose dependent increase in apoptosis of EOMA hemangioma cells, with an increasing 
apoptosis observed at 100 µg/ml, and maximum at 1000 µg/ml. Cells treated with nutrition mixture showed significantly more 
apoptotic changes than the control or camptothecin-treated cells. Conclusion: These results suggest that NM may induce apoptosis 
of hemangioma cells in vitro thus warranting further investigation.
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A hemangioma is a vascular malformation, an ab-
normal buildup of blood vessels in the skin or internal 
organs. Hemangiomas are the most common congeni-
tal vascular and benign tumor in infants and children. 
They are three to five times more common in female 
children than in males and occur more frequently 
in Caucasian infants than in Asian-American or African-
American infants. Between 4–10% of infants have 
at least one hemangioma. Although a hemangioma 
can appear anywhere on the skin, 60% of them occur 
on scalp and face, and about 25% occur on chest, 
and trunk areas, which are the most common sites 
of superficial hemangiomas. The most common site 
of internal organ hemangiomas is liver, kidneys, lungs, 
colon, and brain. Generally, most hemangiomas do not 
cause any symptoms to require intervention. Some 
of the larger hemangiomas have tendency to bleed and 
may require surgical removal. The exact cause of he-
mangioma is unknown. Sometimes, hemangiomas 
can have genetic origin and can be inherited in a family 
as an autosomal dominant characteristic with various 
genetic syndromes [1, 2].
While there are different theories regarding the 
causes of hemangioma, researchers think that he-
mangiomas are an abnormal proliferation of blood ves-
sels and a manifestation of aberrant angiogenesis [3]. 
Abnormal cell proliferation and angiogenesis require 
the following steps for tumor formation: attachment 
of cells to the extra-cellular matrix (ECM), the even-
tual degradation of ECM for cell migration through 
the disrupted matrix. The two families of proteases, 
matrix metalloproteinases (MMP), and urokinase plas-
minogen activator (u-PA), play key roles in tumor cell 
invasion. Experimental studies have demonstrated the 
role of urokinase plasminogen, especially cell surface 
u-PA, as an initiator of ECM proteolysis and associated 
tumor cell invasion. The protease u-PA converts plas-
minogen to plasmin, which is capable of promoting tu-
mor growth and angiogenesis, degrading the ECM and 
basement membrane and activating pro-MMPs [4]. 
Consumption of plant based diet has been associated 
with prevention of the development and progression 
of various tumors.
In other studies, we found that a nutrient mix-
ture (NM) containing lysine, proline, arginine, ascorbic 
acid, and green tea extract demonstrated significant 
antiangiogenic activity [5]. Our previous study also 
reported significant antiangiogenic properties 
of NM in hemangioma cells in vivo and in vitro. In that 
study, we found that the NM significantly affects 
the tumor growth in the hemangioma (EOMA) cells 
in athymic mice [6]. In the current study, we examine, 
whether the antitumor effects of the NM are due to in-
hibition of u-PA and induction of caspase-dependent 
apoptosis.
MATERIALS AND METHODS
Composition of the NM. The stock solution 
of the NM (total weight 4.4 g) used for testing was 
composed of the following in the quantities indicated: 
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vitamin C (as ascorbic acid and as Mg, Ca and palmi-
tate ascorbate) 700 mg, L-lysine 1000 mg; L-proline 
750 mg; L-arginine 500 mg, N-acetyl cysteine 200 mg; 
standardized green tea extract 1000 mg (derived from 
green tea leaves, was obtained from US Pharma Lab; 
the certificate of analysis indicated the following char-
acteristics: total polyphenol, 80%, catechins, 60%; 
epigallocatechin gallate (EGCG), 35% and caffeine, 
1%), selenium 30 mg, copper 2 mg, and manganese 
1 mg.
Cells and cell culture. Hemangioma cell line 
(EOMA) was obtained from ATCC (American Type Cul-
ture Collection, Rockville, MD, USA) and maintained 
in Dulbecco’s Modified Eagle’s Medium (DMEM) 
and supplemented with 10% FBS, 100 U/ml peni-
cillin and 100 mg/ml streptomycin. The media and 
sera were obtained from ATCC, and antibiotics from 
Gibco BRL (Long Island, NY, USA). The cells were 
grown at 37 °C in 5% CO2.
MTT assay. MTT assay was carried out as de-
scribed earlier [6]. Briefly, cell suspensions were plated 
in 24-well tissue culture plates (Nunc, Denmark) 
at a concentration of 3 × 104 cells/well. After incubating 
the plates for 24 h at 37 °C in a humidified incubator, the 
cells were treated with the NM at concentrations of 10, 
100 and 1000 μg/ml for 24 h and the control group was 
left untreated. MTT assay reagent, 0.5 mg/ml (Sigma, 
USA) was added (500 μl per well) followed by 2-hour 
incubation at 37 °C. Following incubation, the solution 
was carefully aspirated from the wells, the formazan 
product was dissolved in 1 ml DMSO, and the absor-
bance (OD) was measured on a microplate reader 
at a wavelength of 570 nm in a BioSpec 1601 Shimadzu 
spectrometer (Scinteck Instruments, Manassas, VA, 
USA). The OD 570 of the DMSO solution in each well was 
considered to be proportional to the number of cells.
Fibrin zymography. Fibrin zymography was 
used to analyze u-PA activity on 10% SDS-PAGE gels 
containing fibrinogen (5.5 mg/ml) and plasminogen 
(50 μg/ml). The sample used was the cell culture 
supernatant treated with NM. After electrophoresis, 
the gels were washed twice with 2.5% Triton X-100 for 
30 min. The gels were then incubated overnight 
at 37 °C with 0.1% glycine buffer pH 7.5 and then 
stained with 0.5% Coomassie Brilliant Blue R250 and 
destained. Electrophoresis of u-PA and tissue plas-
minogen activator were conducted for comparison. 
Fibrin zymograms were scanned using CanoScan 
9950F Canon Scanner (Orem, Utah, USA).
H&E staining. The cells were cultured in 24-well 
plates and were kept either untreated (control group) 
or treated with NM at a concentrations of 50, 500 and 
1000 μg/ml (treatment group). After 24-hour incuba-
tion, the cells were washed with PBS, fixed with cold 
methanol, and then stained with haematoxylin and 
eosin for 5 min each. The stained cells were then ob-
served and imaged by microscopy.
Apoptosis and Live Green Caspase Assay. The 
EOMA hemangioma cells were grown to near conflu-
ence and either left in media alone, or challenged with 
the NM dissolved in media at 0, 100, and 1000 μg/ml, 
and incubated for 24 h. The cell culture was washed 
with PBS and treated with the caspase reagent 
as specified in the manufacturer’s protocol (Molecu-
lar Probes Image-IT Live Green Caspases Detection 
Kit 135104, Invitrogen). Camptothecin 10 μM was 
used as positive control to demonstrate apoptosis. 
The cells were photographed under the fluorescence 
microscope and counted. Green colored cells repre-
sent viable cells, while yellow-orange and red colors 
represent early and late apoptotic cells, respectively.
Statistical analysis. The results were expressed 
as mean ± standard deviation for the groups. Data was 
analyzed by the independent t-test.
RESULTS
Cell viability study. The MTT assay demonstrated 
dose-dependent toxicity with increased NM con-
centration — 10%, 30%, and 55% at 10, 100, and 
1000 μg/ml, respectively. NM exhibited dose response 
toxicity on EOMA cells, with maximum toxicity of 55% 
(p < 0.001) over the control at 1000 μg/ml. There was 
significant negative correlation between NM concen-
tration and cell viability, with p < 0.0001 (Fig. 1).
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Fig. 1. Effect of NM on viability of EOMA cells. *p < 0.001 com-
pared with control cells
Effect of NM on u-PA activity on hemangioma 
EOMA cells. The cells showed two bands correspond-
ing to subunit 1 and 2 of u-PA at 55 kDa for subunit 1. 
NM inhibited the u-PA secretion in a dose dependent 
manner starting at 250 μg/ml and maximum inhibition 
at 1000 μg/ml. The u-PA subunit 1 showed linear trend 
R2 = 0.8571 and for the u-PA subunit 2 the linear trend 
R2 = 0.7714 as shown in Fig. 2, a, b.
Apoptotic morphology by H&E staining. 
H&E staining revealed a similar apoptotic pattern 
in dose dependent fashion in hemangioma EOMA 
cells treated with NM at 0, 50, 500 and 1000 μg/ml. 
This included characteristic morphological changes 
such as the shrinkage of the cytoplasm, and darkly 
stained nuclei with intensely acidophilic cytoplasm. 
These changes were dose dependent that is slight 
changes noticed at 50 μg/ml, moderate to signifi-
cant changes as the NM dose increased to 500 and 
1000 μg/ml as shown in (Fig. 3).
Apoptosis. Analysis with the Live Green Caspase re-
vealed a dose dependent increase in apoptosis of EOMA 
hemangioma cells, with a slight apoptosis observed 
at 100 μg/ml, and maximum at 1000 μg/ml (Fig. 4).
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DISCUSSION
In our earlier in vivo studies, the NM significantly 
inhibited the growth of hemangioma (EOMA) cells 
in athymic mice [6]. In the current study, we inves-
tigated whether this underlying antitumor effect 
of NM was due, in part, to its action of inducing apop-
tosis via activation of caspase enzymes. The stimu-
lation of suppressed apoptotic pathways in cancer 
cells and the induction of apoptosis is a predominant 
mechanism to target cancer. NM induced significant 
apoptosis in the EOMA cells. Moreover, the apoptotic 
changes such as cell shrinkage, nuclear condensation, 
cell membrane asymmetry, and condensation of cy-
toplasm were also evident and increased in a dose-
dependent fashion. We also studied the effect 
of NM on inducing apoptosis using the in vitro Live 
Green Caspase detection method and by using camp-
tothecin as a positive control. Camptothecin is a potent 
inhibitor of topoisomerase I, a molecule required for 
DNA synthesis. It is generally used as an anticancer 
treatment agent to induce apoptosis in solid tumors. 
As seen from the photomicrographs, the green colored 
cells are viable cells, yellow colored cells are in early 
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Fig. 2. Effect of NM on u-PA activity on hemangioma EOMA 
cells: a — inhibition of u-PA secretion; b — linear regression lines
Fig. 3. Effect of NM on morphology of EOMA cells: a — control; b — NM, 50 μg/ml; c — NM, 500 μg/ml; b — NM, 1000 μg/ml. 
H&E staining, magnification × 200
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apoptosis and the red colored cells are in late stages 
of apoptosis. Our study demonstrated that the specific 
mixture of tested nutrients induced significantly more 
apoptosis in EOMA cells than the control and also more 
than camptothecin. NM also inhibited u-PA secretion 
in hemangioma (EOMA) cells.
Congenital hemangiomas are abnormal develop-
ment of blood vessels during embryogenesis. Although 
hemangiomas may resolve spontaneously, some of the 
larger or internal hemangiomas are treated either 
surgically or by drugs. The goal of drug therapy with 
corticosteroids or vincristine is to stop endothelial cell 
proliferation and angiogenesis, and induce apoptosis 
to initiate regression. Degradation of ECM is essential 
process in angiogenesis and vascular remodeling dur-
ing fetal maturation. Studies have shown that elevated 
levels of protease enzymes, such as u-PA are associ-
ated with tumor growth, progression, angiogenesis, 
and metastasis. Endothelial cell proliferation requires 
the critical steps of cell attachment, degradation 
of ECM and migration through the disrupted matrix. 
The serine protease u-PA (a 55-kDa serine protease 
consisting of two disulphide bridges linked to polypep-
tides), is cleaved to the active chain (33 kDa) by various 
stimuli. Furthermore, u-PA also activates and mobilizes 
the angiogenesis inducing factors to the site of hem-
angioma. This enzyme also modulated endothelial 
cell function including migration and growth through 
a mechanism independent of its proteolytic activity [7]. 
Plasmin is critical for hemangioma formation, but may 
not be critical for capillary formation by normal endo-
thelial cells. u-PA converts plasminogen to plasmin and 
the plasmin generated in this acts as a chemotactic 
agent for endothelial cells [7]. Therefore, we examined 
the actions of NM on inhibition of u-PA and observed 
the dose dependent reduction of u-PA. Development 
of antiangiogenic remedies is one of the potential 
targets to treat hemangiomas.
Apoptosis, also known as programmed cell death, 
is a complex process that occurs in several pathologi-
cal situations. Various methods have been developed 
to study apoptosis using multiple up regulation and 
down regulation of specific genes such as Bax and 
p53 genes [8]. One of them is based on the distinc-
tive features of early stage of apoptosis, which is the 
activation of caspase enzymes. The family of caspase 
aspartate — specifically, cysteine proteases is emerg-
ing which plays a central role in apoptosis. Some ex-
amples of these important caspases are caspase-3, 
-7, -8, -9, -10 and so on [9, 10]. Although multiple 
Fig. 4. Effect of NM on apoptosis by caspase induction on EOMA cells: a — control; b — camptothecin, 10 μM; c — NM, 100 μg/ml; 
b — NM, 1000 μg/ml (magnification × 200)
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nutrients have anticancer properties, a study combin-
ing the micronutrients in the appropriate quantities for 
synergistic and enhanced action is lacking.
It has been observed in previous studies that a spe-
cific combination of nutrients such as ascorbic acid, 
EGCG, lysine and proline show a synergistic anticancer 
effect which is much more effective than any of the 
individual nutrients alone [11]. The NM was formulated 
by selecting nutrients that act on critical physiological 
targets in cancer progression and metastasis, as docu-
mented in several studies. Combining these micronu-
trients expands metabolic targets, and maximizes bio-
logical impact with lower doses of components [12, 13].
Surgery and other modalities used in the current 
treatment of hemangiomas are associated with risks 
and side effects. Therefore, they are used only in se-
vere cases. We have demonstrated that NM is safe ac-
cording to our studies in female nude mice and where 
the administration of NM did not have adverse effects 
on vital organs such as heart, liver, kidneys or the 
functional serum markers [14]. With the proven safety 
of NM and the results of our current study we think that 
NM may have potential in treating hemangioma without 
side effects of current treatments.
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